Today, I am going to know about one drug for heart disease. So, teach me. Every day, I am going to learn about one every drug different.
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
I now have comprehensive material from multiple authoritative textbooks. Let me compose a full, structured, easy-to-learn lesson on Metoprolol.
💊 Drug of the Day: Metoprolol
Class: Selective Beta-1 Adrenergic Blocker (Cardioselective Beta-Blocker)
🧠 Quick Overview
| Feature | Details |
|---|---|
| Generic name | Metoprolol |
| Brand names | LOPRESSOR (tartrate), TOPROL XL (succinate) |
| Drug class | Beta-1 selective adrenergic blocker |
| Route | Oral, IV (emergency) |
⚙️ Mechanism of Action
The heart has beta-1 (β1) adrenergic receptors. When adrenaline (epinephrine/norepinephrine) binds these receptors, the heart beats faster and harder - which is bad in many heart conditions.
Metoprolol competitively blocks these β1 receptors. The result:
- Heart rate decreases (negative chronotropy)
- Force of contraction decreases (negative inotropy)
- Blood pressure falls - partly because heart output drops, and partly because renin production (which raises BP) is suppressed
- Myocardial oxygen demand drops - helpful in angina
Why "cardioselective"? Metoprolol is approximately 50-100x less potent at blocking β2 receptors (in lungs, blood vessels) compared to non-selective beta-blockers like propranolol. This matters because β2 blockade causes bronchospasm. So metoprolol is safer in asthmatics - though still not risk-free.
- Katzung's Basic and Clinical Pharmacology, 16th Ed., p. 288
🏥 Clinical Uses (What Heart Conditions Does It Treat?)
1. Heart Failure with Reduced Ejection Fraction (HFrEF)
This is one of metoprolol's biggest roles. Counterintuitively, beta-blockers were once thought harmful in heart failure. But research showed that chronically elevated adrenaline actually destroys the failing heart through remodeling, fibrosis, and arrhythmias. Blocking it improves survival.
The MERIT-HF Trial (the pivotal trial for metoprolol): Metoprolol succinate CR/XL produced a 34% relative reduction in mortality in patients with heart failure. This was so significant the trial was stopped early.
Only 3 beta-blockers have proven mortality benefit in heart failure:
- Metoprolol succinate (Toprol XL)
- Bisoprolol
- Carvedilol
- Braunwald's Heart Disease, p. 154
2. Hypertension
Metoprolol is a first-line agent for high blood pressure, especially in patients who also have heart failure or coronary artery disease.
3. Angina (Chest Pain / Coronary Artery Disease)
Reduces the heart's oxygen demand by slowing heart rate and reducing contractility - giving relief from ischemic chest pain.
4. Acute STEMI (Heart Attack)
Started within 24 hours in hemodynamically stable patients. Dose: 25-50 mg orally every 6-8 hours, titrated up. In high-risk patients with tachycardia or elevated BP, it may be given intravenously.
- Goldman-Cecil Medicine, p. 645
5. Atrial Fibrillation / Arrhythmias
Used for rate control - slows conduction through the AV node to prevent the ventricles from beating too fast.
💊 Formulations & Dosing
| Formulation | Brand | Key Feature |
|---|---|---|
| Metoprolol tartrate | Lopressor | Short-acting, half-life ~4-6 hours, dosed 2-3x/day |
| Metoprolol succinate | Toprol XL | Extended-release, dosed once daily |
For heart failure - always use the succinate (XL) form. The tartrate form did NOT show the same mortality benefit.
Doses are started low and titrated up (e.g., 12.5-25 mg/day, doubling every 2 weeks as tolerated, target ~200 mg/day for HF).
⚠️ Adverse Effects
| Side Effect | Why It Happens |
|---|---|
| Bradycardia | Too much β1 blockade slows the SA node |
| Fatigue / cold extremities | Reduced cardiac output and peripheral vasoconstriction |
| Hypotension | Expected extension of the BP-lowering effect |
| Bronchospasm | Partial β2 blockade (less than propranolol, but possible) |
| Masking hypoglycemia | β-blockers blunt tachycardia that warns of low blood sugar |
| Worsening HF initially | Negative inotropic effect at start - give low dose, titrate slowly |
| Withdrawal syndrome | Abrupt stopping can cause rebound tachycardia, angina, even MI |
Never stop metoprolol abruptly - taper the dose over 1-2 weeks.
🚫 Contraindications
- Severe bradycardia (heart rate < 50 bpm)
- High-degree AV block (2nd or 3rd degree) without a pacemaker
- Cardiogenic shock
- Decompensated acute heart failure
- Severe reactive airway disease (relative contraindication)
🔬 Key Pharmacokinetics
| Parameter | Metoprolol |
|---|---|
| Metabolism | Extensively by CYP2D6 in the liver |
| First-pass effect | High - reduces oral bioavailability |
| Half-life (tartrate) | ~4-6 hours |
| Half-life (succinate XL) | ~12 hours (extended release) |
| Drug interactions | CYP2D6 inhibitors (amiodarone, fluoxetine, duloxetine) increase metoprolol levels and adverse effects |
Genetic note: "Poor metabolizers" of CYP2D6 have doubled metoprolol half-life and are ~5x more likely to develop adverse effects after oral dosing.
- Barash Clinical Anesthesia, 9e; Katzung Pharmacology, 16th Ed.
🆚 Quick Comparison: Metoprolol vs. Other Beta-Blockers
| Drug | Selectivity | Main Use |
|---|---|---|
| Metoprolol | β1-selective | HF, HTN, angina, STEMI, AF |
| Carvedilol | Non-selective (α1+β1+β2) | HF (more potent, but more side effects) |
| Bisoprolol | β1-selective | HF, HTN |
| Propranolol | Non-selective (β1+β2) | HTN, migraine, tremor, hyperthyroidism |
🧠 Memory Trick
"Metro = Heart's traffic controller" Just like a metro system slows traffic in a busy city, Metoprolol slows the heart - fewer beats, less oxygen demand, less workload. The XL version runs all day (once daily), while the regular version needs multiple trips (2-3x/day).
📝 Quick Revision Summary
- Class: Cardioselective β1-blocker
- Mechanism: Blocks β1 receptors → slower HR, lower BP, less O2 demand
- Key uses: Heart failure (HFrEF), hypertension, angina, STEMI, atrial fibrillation
- Proven mortality benefit: MERIT-HF trial (34% mortality reduction in HF)
- Only the succinate form reduces mortality in HF (not tartrate)
- Side effects: Bradycardia, fatigue, hypotension, bronchospasm, glucose masking
- Never stop abruptly - rebound tachycardia/angina risk
- CYP2D6 metabolism - watch for drug interactions
Sources:
- Katzung's Basic and Clinical Pharmacology, 16th Ed. - Metoprolol & Atenolol section, p. 288
- Braunwald's Heart Disease, 2 Vol Set - Beta-Blockers chapter, p. 153-154
- Lippincott Illustrated Reviews: Pharmacology - β-Adrenoreceptor Blockers, p. 352-360
- Goldman-Cecil Medicine International Edition - β-Adrenergic Blockers, p. 645
Come back tomorrow and I'll teach you a different heart drug! Some good options for your next session:
- Atorvastatin (statin for cholesterol/heart protection)
- Lisinopril (ACE inhibitor for heart failure/hypertension)
- Amiodarone (anti-arrhythmic)
- Furosemide (diuretic for heart failure fluid relief)
Which one would you like next? 🫀
This is a shared conversation. Sign in to Orris to start your own chat.